AstraZeneca stock trades flat as buyers maintain support despite mixed momentum signals

Traders Union
All News
Stocks
AstraZeneca steady at GBX12,626 today

Highlights

Ultomiris gained accelerated US approval as the first treatment for immunoglobulin A nephropathy, giving AstraZeneca a lead in this rare disease area.
AstraZeneca partnered with Oracle to use artificial intelligence and real-world data to improve clinical trial candidate selection and streamline research productivity.
AstraZeneca stock shows strong short- and medium-term buying with an expected trading range of GBX12,398 to GBX12,853 in the coming days.

Regulatory wins and R&D deals boost market potential and momentum

AstraZeneca's Ultomiris has secured accelerated approval in the United States as the first and only treatment for immunoglobulin A nephropathy (IgAN), expanding the drug's market potential and establishing a first-mover advantage in this rare disease segment, according to Advfn. In parallel, AstraZeneca and Oracle have agreed to collaborate on leveraging artificial intelligence and real-world data approaches to optimize clinical trial candidate recruitment, a development that could streamline trial timelines and enhance R&D productivity, Clinicaltrialsarena reports. AstraZeneca and Amgen also achieved positive Phase III results for Tezspire in the treatment of eosinophilic esophagitis (EoE), adding evidence for its efficacy in an expanded patient population, as highlighted by Marketscreener.

Buyer momentum prevails as price holds above key supports

AZN is trading above its MA-20 at GBX12,548 and MA-50 at GBX12,474, but remains below the MA-200 at GBX13,470 on the daily timeframe. The Ichimoku Kijun sits at GBX12,495 and acts as immediate support. Both MACD and ADX are on buy signals, with RSI reading 61.7 and CCI also in buy territory. However, Stoch RSI and the Awesome Oscillator are neutral. Bull/Bear Power registers overbought levels, reflecting persistent buyer dominance on an intraday basis. The mixed oscillator readings indicate partial divergence even as momentum trends remain tilted toward buyers.

Upside breakout likely as consolidation persists within trading range

In the short term, AZN is expected to trade within the range of GBX12,398 to GBX12,853, reflecting typical volatility relative to its current levels. A likely scenario is that price consolidates within this corridor, with a very high probability of upside breakout toward the upper boundary if current momentum persists. A less probable downside scenario would see the price breach immediate support and test the lower end of the range.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca showing stable technicals but notes the price remains capped below long-term averages. He highlights strong fundamentals, as Ultomiris approval and positive trial news strengthen the pipeline, yet overall price action is flat and some indicators diverge. The analyst stays defensive and emphasizes that upside potential is contingent on sustaining current momentum. "Until GBX13,470 is reclaimed, I remain cautious and view rallies as limited in scope."

Earlier, analysts noted that AstraZeneca was likely to remain in a consolidation phase, supported by positive developments in its clinical pipeline and increasing integration of AI-driven research. The current article adds material fundamental support with Ultomiris's accelerated US approval and further advances in AI collaborations, prompting traders to monitor for a potential breakout should momentum persist near the upper end of AZN's present trading range.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.